0001193125-20-107782.txt : 20200608 0001193125-20-107782.hdr.sgml : 20200608 20200415102902 ACCESSION NUMBER: 0001193125-20-107782 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20200415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 CORRESP 1 filename1.htm CORRESP
LOGO   

ROPES & GRAY LLP

PRUDENTIAL TOWER

800 BOYLSTON STREET

BOSTON, MA 02199-3600

WWW.ROPESGRAY.COM

   

April 15, 2020

BY EDGAR TRANSMISSION

 

Re:

Sarepta Therapeutics, Inc.

Preliminary Proxy Statement on Schedule 14A

Filed on April 8, 2020 by Sarepta Therapeutics, Inc.

SEC Comment Letter dated April 13, 2020

File No. 001-14895

Ladies and Gentlemen:

On behalf of Sarepta Therapeutics, Inc. (the “Company”), we are providing the Company’s response to the comment in the letter, dated April 13, 2020 (the “Comment Letter”), of the staff (the “Staff”) of the Securities and Exchange Commission with respect to the Company’s above-referenced preliminary proxy statement on Schedule 14A filed on April 8, 2020.

The Staff’s comment, as reflected in the Comment Letter, is reproduced in italics in this letter, and the response of the Company is shown below the comment.

Preliminary Proxy Statement on Schedule 14A

Restated Certificate Amendment (Proposal 3), page 19

 

1.

Please revise the proxy statement to indicate whether you currently have any plans, arrangements or understandings, written or oral, to issue any of the authorized but unissued shares that would become available as a result of the amendment to the Restated Certificate.

In response to the Staff’s comment, the Company will add the following disclosure under the heading “Restated Certificate Amendment (Proposal 3)—Purpose and Effect of the Proposal” in its definitive proxy statement on Schedule 14A: “Other than with respect to Proposal 4, the Company has no definitive plan, arrangement, or understanding to issue the additional shares of common stock.”

If you have any questions or comments about this letter or need any further information, please direct any communications to the undersigned at (617) 951-7921 or paul.kinsella@ropesgray.com or to my colleague, Raymond Grant at (617) 235-4668 or raymond.grant@ropesgray.com.

Respectfully Submitted,

 

/s/ Paul M. Kinsella

Paul M. Kinsella
 GRAPHIC 2 g883667g0415045258914.jpg GRAPHIC begin 644 g883667g0415045258914.jpg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end